Topics

Drinking Water Wastewater Treatment Smart Water Asset Management Water Utility Management

Resources

Global Thought Leaders Events Magazine WaterWorldTV White Papers Webcasts

User Tools

Subscribe Advertise About Us Contact Us Privacy Policy Terms & Conditions

Press Releases

https://www.facebook.com/waterworldmag

https://www.linkedin.com/showcase/waterworld-magazine/about/

https://twitter.com/WaterWorld

Recent Quotes

My Watchlist

Indicators

WaterWorld Market Index

Markets:

Overview

News

Currencies

International

Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

1.180 -0.020 (-1.68%)

Streaming Delayed Price Updated: 10:45 AM EDT, Aug 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

August 11, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...

Via Newsfile

Topics Intellectual Property

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 06, 2026

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...

Via Newsfile

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

July 21, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

July 15, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Topics Intellectual Property

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

June 26, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

June 26, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

June 25, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

June 24, 2026

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in...

Via Newsfile

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

June 23, 2026

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

June 18, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

May 26, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

May 12, 2026

Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio...

Via Newsfile

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 07, 2026

Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7,...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

April 23, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

April 13, 2026

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR....

Via Newsfile

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

April 09, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

March 30, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

March 23, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

March 16, 2026

Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well...

Via Newsfile

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

March 13, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

March 10, 2026

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

March 10, 2026

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at...

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

March 10, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

March 05, 2026

Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

March 05, 2026

Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b...

Via Newsfile

Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company

February 23, 2026

Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, With No Serious Adverse Events

Via TheNewswire.com

Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company

February 23, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

February 19, 2026

Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and...

Via Newsfile

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

https://www.facebook.com/waterworldmag

https://www.linkedin.com/showcase/waterworld-magazine/about/

https://twitter.com/WaterWorld

Subscribe
About Us
Contact Us
Do Not Sell or Share
Privacy Policy
Terms & Conditions